Dr Philippe Bulet, PhD: Emeritus Research Director at CNRS, UMR 7178 - Institut Pluridisciplinaire Hubert Curien (IPHC), Département Sciences Analytiques (DSA), Laboratoire de Spectrométrie de Masse Bio-Organique (LSMBO), Strasbourg (France). Director of the BioPark Platform in Archamps (France). He obtained his PhD in 1984 from the University of Lille (France). He progressed through various team management positions at the laboratory of Professor JA Hoffmann, winner of the 2011 Nobel Prize in Medicine or Physiology. From 2002 to 2008, he was Chief Scientific Officer of a Swiss biotech company specialising in venoms and bioactive molecules. He has published over 225 scientific contributions in international peer-reviewed journals, including 21 book chapters and reviews on bioactive peptides. He co-founded the NP2D (Natural Peptides to Drugs) congress. He is also the co-founder of two biotech companies: EntoMed SA in France and Funzyme Biotechnologies in Switzerland. He is the co-author of thirteen patents in the field of innovative antibiotics. He is president of the French research network on the multifunctionality of antimicrobial peptides. Since 2008, he has been Director of the BioPark, a life sciences platform hosting public and private research.